OmegaD

OmegaD is a private U.S. healthcare/pharmaceutical company that has sponsored clinical development of OmegaD softgels for dry eye disease. Publicly visible evidence indicates the company has focused on an oral omega-3 fatty acid softgel product containing eicosapentaenoic acid and docosahexaenoic acid in triglyceride form. The company has run at least two completed Phase 3 clinical studies in dry eye disease, both listed on ClinicalTrials.gov under OmegaD LLC as sponsor. Available public information suggests OmegaD is a single-asset or highly concentrated company rather than a diversified biotech platform business. There is limited public disclosure about broader operations, financing, commercialization, partnerships, or corporate infrastructure.